Side Effects Naomi Watts Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Naomi Watts Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Confirmed or speculated: Confirmed. Watts has discussed HRT use in her own words across multiple media appearances.
  • Associated medications: Hormone replacement therapy (estrogen-containing; specific formulation not publicly disclosed).
  • Public platform: Founder of Stripes Beauty, a menopause-focused skincare and wellness brand launched 2022.
  • Symptoms she has described publicly: Early menopause onset, sleep disruption, mood changes, brain fog, vaginal dryness, skin changes.
  • Clinical relevance: Each of these maps onto Phase II/III trial data and the FDA-approved label for combined HRT products.
  • HealthRX Medical Team angle: Watts's public account is clinically accurate in its descriptions, but the decision to use HRT involves a risk-benefit analysis that no brand or interview can fully capture.

Why Naomi Watts's Menopause Story Is Different From Most Celebrity Disclosures

Most celebrity health disclosures are either vague ("I changed my lifestyle") or commercially motivated in ways that strip out clinical nuance. Watts's case is different for two reasons. First, she has been unusually specific about the symptoms she experienced. Second, she entered perimenopause early, at around age 36 by her own account, which places her in a clinically distinct population compared to women who reach menopause at the median age of 51.

In a 2023 interview with People magazine, Watts described her perimenopause onset as abrupt and disorienting: she spoke about cognitive fog, disrupted sleep, and emotional volatility arriving before she had any framework to interpret them. She has since said, across multiple public appearances and on the Stripes Beauty website, that HRT became a central part of her management strategy.

She has not, as of this writing, publicly disclosed a specific formulation, dose, delivery route, or prescribing physician. Any claims beyond "HRT" would be speculation, and this page will not make them.

The Symptoms Watts Has Described Publicly, One by One

1. Sleep Disruption

In a 2022 interview with Harper's Bazaar, Watts described difficulty sleeping as one of the first and most debilitating symptoms she noticed. She used the word "exhausting" to characterize the cumulative effect.

What the clinical literature says: Sleep disruption is among the most consistent findings in menopause research. Vasomotor symptoms (hot flashes and night sweats) are the primary driver, but declining estrogen also directly affects sleep architecture, reducing slow-wave sleep and increasing arousals. A 2015 meta-analysis in Menopause found that estrogen therapy significantly improved subjective and objective sleep quality versus placebo. The FDA prescribing information for Climara Pro (an estradiol/levonorgestrel transdermal system) lists insomnia as an adverse event reported in clinical trials, occurring in roughly 5-8% of users, which means HRT can also cause or worsen sleep disruption in some patients, a nuance rarely discussed in advocacy contexts.

2. Brain Fog and Cognitive Changes

Watts described cognitive sluggishness and difficulty concentrating in a 2023 conversation on the Stripes Beauty Instagram, characterizing it as something that made her feel "not like herself."

What the clinical literature says: The relationship between estrogen and cognition is real but complicated. Estrogen receptors are present throughout the brain, including in regions tied to memory and executive function. A 2014 review in Neuroscience and Biobehavioral Reviews documented that estrogen modulates acetylcholine and serotonin pathways relevant to cognitive function. The timing of HRT initiation matters significantly: the "critical window hypothesis" holds that estrogen started close to menopause onset may be neuroprotective, while initiation years later may carry different risk profiles. This distinction was highlighted in the Women's Health Initiative Memory Study, which found increased dementia risk when conjugated equine estrogen plus medroxyprogesterone acetate was started in women aged 65 and older, a cohort quite different from a woman in her late 30s managing perimenopause.

3. Mood Instability and Anxiety

In a 2022 interview with Today, Watts spoke candidly about emotional volatility and what she described as heightened anxiety during perimenopause. She has connected HRT to stabilization of her mood, though she has not described this as a cure.

What the clinical literature says: Estradiol has demonstrated antidepressant-like effects in perimenopausal women in several controlled trials. A 2018 randomized trial in JAMA Psychiatry found that transdermal estradiol with intermittent micronized progesterone reduced the likelihood of developing clinically significant depressive symptoms in perimenopausal and early postmenopausal women by approximately 32% versus placebo. Mood changes, including depression, nervousness, and affect lability, are also listed as adverse events in the FDA labeling for combined HRT products, meaning the relationship runs in both directions depending on the individual and formulation.

4. Vaginal Dryness and Genitourinary Symptoms

Watts has spoken about genitourinary symptoms, including vaginal dryness, in the context of why she wanted to reduce stigma around menopause conversations. She addressed this directly in a 2022 BBC interview and on the Stripes Beauty website.

What the clinical literature says: Genitourinary syndrome of menopause (GSM) affects an estimated 27-84% of postmenopausal women and includes vaginal dryness, dyspareunia, and urinary symptoms. Unlike vasomotor symptoms, GSM tends to worsen over time without treatment. Both systemic and local (vaginal) estrogen therapy are effective; a 2016 Cochrane review confirmed that local estrogen preparations relieve GSM symptoms with minimal systemic absorption. For women who prefer or require non-systemic options, ospemifene (an oral selective estrogen receptor modulator) is an FDA-approved alternative.

5. Skin and Hair Changes

The Stripes Beauty brand specifically targets skin changes associated with menopause, and Watts has discussed collagen loss and skin texture shifts in multiple brand-related interviews.

What the clinical literature says: Skin estrogen receptors regulate collagen synthesis, moisture retention, and wound healing. Studies including a 2007 review in the American Journal of Clinical Dermatology documented that skin collagen content decreases approximately 30% in the first five postmenopausal years. Systemic HRT has been associated with improvements in skin thickness and collagen content in observational studies, though large randomized trial data are limited. Topical estrogen applied to skin has shown local effects in small trials, but this is not a standard FDA-approved indication.

The Side-Effect Profile That Rarely Gets Discussed in Advocacy

Watts's public messaging about HRT is broadly positive, and her account of symptom relief is consistent with the clinical evidence. What gets less airtime in celebrity-driven menopause advocacy is the documented adverse-event profile, which is real and relevant for any woman considering treatment.

FDA prescribing information for combined estrogen-progestogen products lists the following adverse events reported in trials at rates above placebo: breast pain or tenderness, uterine bleeding or spotting, headache, nausea, bloating, and peripheral edema. Serious risks, including venous thromboembolism, stroke, and, for combined HRT specifically, a small increase in breast cancer incidence with prolonged use, carry black-box warnings.

The absolute risk magnitudes are frequently misunderstood. The Women's Health Initiative found that for women aged 50-59 initiating combined HRT, the absolute excess risk of breast cancer was approximately 8 additional cases per 10,000 person-years. For women in that same age group, HRT was associated with reduced all-cause mortality in several analyses, including a 2017 paper in JAMA Internal Medicine. Risk-benefit calculations are highly individualized and depend on age, time since menopause, personal and family history, and formulation.

The HealthRX Medical Team take: Watts's public account is medically coherent. Every symptom she has named is documented in the clinical record. Her advocacy has likely reached women who were previously unaware that their symptoms were treatable. The gap in celebrity HRT coverage, including in Watts's public statements, is the side-effect conversation. HRT is not appropriate for every perimenopausal woman, and the decision requires individualized risk assessment with a clinician who has access to the patient's full history. No skincare brand, no matter how well-intentioned, can substitute for that evaluation.

What Watts Has Not Publicly Addressed

She has not disclosed the specific estrogen compound she uses (estradiol versus conjugated equine estrogen), the delivery method (oral, transdermal patch, gel, cream, vaginal ring), whether she uses a progestogen component, or current dose. These details matter clinically. Transdermal estradiol, for example, carries a lower thrombosis risk than oral estrogen because it bypasses first-pass hepatic metabolism, per a 2010 case-control study in Circulation. Without knowing her regimen, readers should not assume her experience generalizes to any particular product.

Frequently asked questions

›
›
›
›
›

References

  • Watts, Naomi. Interview. People magazine. 2023. https://people.com/health/naomi-watts-menopause-stripes-beauty/
  • Watts, Naomi. Interview. Harper's Bazaar. 2022. https://www.harpersbazaar.com/celebrity/latest/a39801359/naomi-watts-menopause-stripes-beauty/
  • Watts, Naomi. Interview. Today. 2022. https://www.today.com/health/womens-health/naomi-watts-menopause-stripes-beauty-rcna25849
  • Watts, Naomi. Interview. BBC. 2022. https://www.bbc.com/news/entertainment-arts-62124953
  • Stripes Beauty Instagram. 2023. https://www.instagram.com/stripes_beauty/
  • FDA Prescribing Information, Climara Pro (estradiol/levonorgestrel). 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021371s016lbl.pdf
  • Ensrud KE, et al. "Sleep disturbances and menopause." Menopause. 2015. https://pubmed.ncbi.nlm.nih.gov/25647647/
  • Sherwin BB. "Estrogen and cognitive aging in women." Neuroscience & Biobehavioral Reviews. 2014. https://pubmed.ncbi.nlm.nih.gov/24704566/
  • Shumaker SA, et al. "Women's Health Initiative Memory Study." JAMA. 2003. https://pubmed.ncbi.nlm.nih.gov/12771112/
  • Gordon JL, et al. "Efficacy of transdermal estradiol for preventing depressive symptoms." JAMA Psychiatry. 2018. https://pubmed.ncbi.nlm.nih.gov/29490333/
  • Lethaby A, et al. "Local oestrogen for vaginal atrophy." Cochrane Database. 2016. https://pubmed.ncbi.nlm.nih.gov/27677673/
  • Thornton MJ. "Estrogens and aging skin." American Journal of Clinical Dermatology. 2007. https://pubmed.ncbi.nlm.nih.gov/17324120/
  • Rossouw JE, et al. Women's Health Initiative. NEJM. 2002. https://www.nejm.org/doi/full/10.1056/NEJMoa030808
  • Manson JE, et al. "Menopausal HRT and mortality." JAMA Internal Medicine. 2017. https://pubmed.ncbi.nlm.nih.gov/28346582/
  • Canonico M, et al. "Hormone therapy and venous thromboembolism." Circulation. 2010. https://pubmed.ncbi.nlm.nih.gov/20644542/
  • The Menopause Society. 2023 Position Statement on Hormone Therapy. https://menopause.org/for-women/menopauseflashes/menopause-blog/the-2023-menopause-society-hormone-therapy-position-statement-what-you-need-to-know
  • CDC. Menopause. https://www.cdc.gov/reproductivehealth/womensrh/menopause.html